Clinical Trial Results: Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors [Phase 2]

View source ↗

Summary

Phase 2 trial results for nab-sirolimus in patients with well-differentiated neuroendocrine tumors (NETs) of the gastrointestinal tract, lung, or pancreas who h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Neuroendocrine Tumor
• Neuroendocrine Tumors
• Pancreatic Neuroendocrine Tumor
• Pulmonary Neuroendocrine Tumor

Drugs mentioned

• nab-sirolimus (sirolimus (nanoparticle albumin-bound formulation))

Snippet

Sponsor: Aadi Bioscience, Inc. | Conditions: Neuroendocrine Tumors, NET | Phase 2 | Status: COMPLETED | Results posted: 2026-08-25